Výsledky vyhledávání - "псориаз"
-
1
-
2
-
3
-
4
-
5
Zdroj: Российские биомедицинские исследования, Vol 9, Iss 4 (2025)
Přístupová URL adresa: https://doaj.org/article/2ba3f184411b443c8eda25e2f1fd738e
-
6
Autoři:
Zdroj: Медицина в Кузбассе, Vol 24, Iss 1, Pp 44-51 (2025)
Témata: неалкогольная жировая болезнь печени, псориаз, коморбидность, урсодезоксихолевая кислота, Medicine
Popis souboru: electronic resource
Relation: https://mednauki.ru/index.php/MK/article/view/1220; https://doaj.org/toc/1819-0901; https://doaj.org/toc/2588-0411
Přístupová URL adresa: https://doaj.org/article/cbf80201317545bea863c6ef330a9560
-
7
-
8
-
9
-
10
-
11
Zdroj: Медицина в Кузбассе, Vol 24, Iss 1, Pp 44-51 (2025)
Témata: коморбидность, Medicine, псориаз, урсодезоксихолевая кислота, неалкогольная жировая болезнь печени
Přístupová URL adresa: https://doaj.org/article/cbf80201317545bea863c6ef330a9560
-
12
Autoři: a další
Zdroj: Meditsinskiy sovet = Medical Council; № 23 (2024); 199-204 ; Медицинский Совет; № 23 (2024); 199-204 ; 2658-5790 ; 2079-701X
Témata: Акридерм СК, betamethasone, psoriasis, scalp psoriasis, glucocorticosteroids, solution, Akriderm SK, бетаметазон, псориаз, псориаз волосистой части головы, глюкокортикостероиды, раствор
Popis souboru: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8847/7755; Матушевская ЕВ, Коновалова МВ, Владимирова ЕВ, Свирщевская ЕВ. Патогенез и терапия псориаза и псориатического артрита. Клиническая дерматология и венерология. 2019;18(5):626–634. https://doi.org/10.17116/klinderma201918051626.; Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265. https://doi.org/10.1016/j.jaad.2018.06.027.; Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5–32. https://doi.org/10.1002/art.40726.; Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R et al. Longterm safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;80(1):282–285. https://doi.org/10.1016/j.jaad.2018.09.002.; Кубанов АА, Карамова АЭ, Притуло ОА, Аршинский МИ, Знаменская ЛФ, Чикин ВВ и др. Псориаз: клинические рекомендации. М.; 2023. Режим доступа: https://cr.minzdrav.gov.ru/recomend/234_2.; Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. https://doi.org/10.1001/jama.2020.4006.; Benhadou F, Mintoff D, Del Marmol V. Psoriasis: Keratinocytes or Immune Cells – Which Is the Trigger? Dermatology. 2019;235(2):91–100. https://doi.org/10.1159/000495291.; Stewart CR, Algu L, Kamran R, Leveille CF, Abid K, Rae C, Lipner SR. The Impact of Nail Psoriasis and Treatment on Quality of Life: A Systematic Review. Skin Appendage Disord. 2021;7(2):83–89. https://doi.org/10.1159/000512688.; Meneguin S, de Godoy NA, Pollo CF, Miot HA, de Oliveira C. Quality of life of patients living with psoriasis: a qualitative study. BMC Dermatol. 2020;20(1):22. https://doi.org/10.1186/s12895-020-00116-9.; Egeberg А, See К, Garrelts А, Burge R. Epidemiology of psoriasis in hardtotreat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3. https://doi.org/10.1186/s12895-020-00099-7.; Nakamura M, Koo J. Safety considerations with combination therapies for psoriasis. Expert Opin Drug Saf. 2020;19(4):489–498. https://doi.org/10.1080/14740338.2020.1722640.; Bernardini N, Skroza N, Tolino E, Marchesiello A, Mambrin A, Balduzzi V et al. Benefit of a topic ointment as co-medication with biologic drugs for the management of moderate-severe psoriasis: a prospective, observational real-life study. Clin Ter. 2020;171(4): e310–e315. https://doi.org/10.7417/CT.2020.2234.; Hadeler E, Mosca M, Hong J, Brownstone N, Bhutani T, Liao W. Nail Psoriasis: A Review of Effective Therapies and Recommendations for Management. Dermatol Ther. 2021;11(3):799–831. https://doi.org/10.1007/s13555-021-00523-x.; Rigopoulos D, Rompoti N, Gregoriou S. Management of Nail Psoriasis. Dermatol Clin. 2021;39(2):211–220. https://doi.org/10.1016/j.det.2020.12.014.; Платонова АВ, Жуков АС, Хайрутдинов ВР, Самцов АВ. Псориатическая ониходистрофия: индексы оценки степени тяжести (часть 2). Вестник дерматологии и венерологии. 2019;95(1):9–14. https://doi.org/10.25208/0042-4609-2019-95-1-9-14.
-
13
Zdroj: Высшая школа: научные исследования.
-
14
Autoři:
Zdroj: Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, Vol 22, Iss 5, Pp 458-464 (2024)
Témata: псориаз, психические расстройства, зуд, нейропептиды, Medicine
Popis souboru: electronic resource
Relation: http://journal-grsmu.by/index.php/ojs/article/view/3198; https://doaj.org/toc/2221-8785; https://doaj.org/toc/2413-0109
Přístupová URL adresa: https://doaj.org/article/796da59cabb146008abbbe57aea22a07
-
15
Autoři:
Zdroj: Eurasian Journal of Medical and Natural Sciences; Vol. 5 No. 10 (2025): Eurasian Journal of Medical and Natural Sciences; 76-80 ; Евразийский журнал медицинских и естественных наук; Том 5 № 10 (2025): Евразийский журнал медицинских и естественных наук; 76-80 ; Yevrosiyo tibbiyot va tabiiy fanlar jurnali; Jild 5 Nomeri 10 (2025): Евразийский журнал медицинских и естественных наук; 76-80 ; 2181-287X
Témata: Псориаз (Psoriasis),ПУВА-терапия (PUVA therapy), Узкополосная УФБ-терапия (Narrowband UVB, NB-UVB therapy), Фототерапия (Phototherapy), PASI (Psoriasis Area and Severity Index), Эффективность лечения (Treatment efficacy), Безопасность (Safety), Побочные эффекты (Adverse effects), Иммуномодулирующее действие (Immunomodulatory effect), Ремиссия (Remission duration), Psoriasis, PUVA therapy, Narrowband UVB (NB-UVB) therapy, Phototherapy, Treatment efficacy, Safety, Adverse effects, Immunomodulatory effect, Remission duration, Uzbekistan
Popis souboru: application/pdf
-
16
Autoři:
Zdroj: Medicine in Kuzbass; Том 24, № 1 (2025): март; 44-51 ; Медицина в Кузбассе; Том 24, № 1 (2025): март; 44-51 ; 2588-0411 ; 1819-0901
Témata: non-alcoholic fatty liver disease, psoriasis, comorbidity, ursodeoxycholic acid, неалкогольная жировая болезнь печени, псориаз, коморбидность, урсодезоксихолевая кислота
Popis souboru: text/html; application/pdf
-
17
Autoři: a další
Přispěvatelé: a další
Zdroj: Vestnik dermatologii i venerologii; Vol 101, No 1 (2025); 50-58 ; Вестник дерматологии и венерологии; Vol 101, No 1 (2025); 50-58 ; 2313-6294 ; 0042-4609 ; 10.25208/vdv.1011
Témata: psoriasis, blood cytokines, cytokine network, psoriatic arthritis, IL-12/IL-23 inhibitor ustekinumab, псориаз, цитокины крови, цитокиновая сеть, псориатический артрит, ингибитор IL-12/IL-23 устекинумаб
Popis souboru: application/pdf
Relation: https://vestnikdv.ru/jour/article/view/16814/pdf_1; https://vestnikdv.ru/jour/article/view/16814/pdf; https://vestnikdv.ru/jour/article/downloadSuppFile/16814/158794; https://vestnikdv.ru/jour/article/downloadSuppFile/16814/158795; https://vestnikdv.ru/jour/article/downloadSuppFile/16814/158796; https://vestnikdv.ru/jour/article/downloadSuppFile/16814/158800; https://vestnikdv.ru/jour/article/downloadSuppFile/16814/158801; https://vestnikdv.ru/jour/article/downloadSuppFile/16814/159231; https://vestnikdv.ru/jour/article/view/16814
-
18
Autoři: a další
Přispěvatelé: a další
Zdroj: Vestnik dermatologii i venerologii; Vol 101, No 1 (2025); 28-49 ; Вестник дерматологии и венерологии; Vol 101, No 1 (2025); 28-49 ; 2313-6294 ; 0042-4609 ; 10.25208/vdv.1011
Témata: psoriasis, psoriatic arthritis, systemic therapy, prescription algorithms, псориаз, псориатический артрит, системная терапия, алгоритмы назначения
Popis souboru: application/pdf
-
19
Autoři: a další
Zdroj: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 70, № 1 (2025); 75-81 ; Российский вестник перинатологии и педиатрии; Том 70, № 1 (2025); 75-81 ; 2500-2228 ; 1027-4065
Témata: секакинумаб, juvenile psoriatic arthritis, psoriasis, secukinumab, ювенильный псориатический артрит, псориаз
Popis souboru: application/pdf
Relation: https://www.ped-perinatology.ru/jour/article/view/2143/1570; Чебышева С.Н., Геппе Н.А., Жолобова Е.С., Алексанян К.В., Мелешкина А.В., Дагбаева Д.В. Клинические особенности псориатического артрита в детском возрасте. Доктор.Ру 2020; 19(10): 22–26.; Ansell B.M., Bywaters E.G. Diagnosis of «probable» Still’s disease and its outcome. Ann Rheum Dis 1962; 21(3): 253–262. DOI:10.1136/ard.21.3.253; Круглова Л.С., Бакулев А.Л., Коротаева Т.В. [и др. Псориаз. Москва; ГЭОТАР-Медиа, 2022; 320.; Chebysheva S.N., Zholobova E.S., Geppe N.A. Features of psoriatic skin lesions in children with juvenile psoriatic arthritis. New Armenian Med J 2021; 15(1): 95–99.; Bodemer C., Kaszuba A., Kingo K., Tsianakas A., Morita A., Rivas E., et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol 2021; 35(4): 938–947. DOI:10.1111/jdv.17002; Brunner H.I., Foeldvari I., Alexeeva E., Ayaz N.A., Calvo Penades I., et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis 2023; 82(1): 154–160. DOI:10.1136/ard-2022–222849; Nelson M.C., Manos C.K. Secukinumab Therapy in Refractory Juvenile Idiopathic Arthritis. J Investig Med High Impact Case Rep 2023; 11: 23247096231200403. DOI:10.1177/232470962312004039; Wallace C.A., Giannini E.H., Huang B., Itert L., Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011; 63(7): 929–936. DOI:10.1002/acr.20497
-
20
Autoři: a další
Zdroj: Meditsinskiy sovet = Medical Council; № 2 (2025); 50-58 ; Медицинский Совет; № 2 (2025); 50-58 ; 2658-5790 ; 2079-701X
Témata: коморбидность, IL-17 inhibitors, psoriasis, oncology, biomarkers, inflammation, comorbidity, ингибиторы ИЛ-17, псориаз, онкология, биомаркеры, воспаление
Popis souboru: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8948/7777; Calapai F, Mannucci C, Cardia L, Currò M, Calapai G, Esposito E, Ammendolia I. Suspected oncologic adverse reactions associated with interleukin-23 inhibitors in EudraVigilance: Comparative study and gender distribution. Pharmacol Res Perspect. 2023;11(5):e01130. https://doi.org/10.1002/prp2.1130.; Crisafulli S, Bertino L, Fontana A, Calapai F, Ingrasciotta Y, Berretta M et al. Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies. Front Oncol. 2021;11:687432. https://doi.org/10.3389/fonc.2021.687432.; Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945–1960. https://doi.org/10.1001/jama.2020.4006.; Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40. https://doi.org/10.1016/j.jaad.2018.06.057.; Kamata M, Tada Y. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int J Mol Sci. 2020;21(5):1690. https://doi.org/10.3390/ijms21051690.; Ceccarelli M, Venanzi Rullo E, Berretta M, Cacopardo B, Pellicanò GF, Nunnari G et al. New Generation Biologics for the Treatment of Psoriasis and Psoriatic Arthritis. State of the Art and Considerations About the Risk of Infection. Dermatol Ther. 2021;34(1):e14660. https://doi.org/10.1111/dth.14660.; Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard MA et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27(Suppl. 3):36–46. https://doi.org/10.1111/jdv.12165.; Battista T, Gallo L, Martora F, Fattore D, Potestio L, Cacciapuoti S et al. Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. J Clin Med. 2024;13(7):1940. https://doi.org/10.3390/jcm13071940.; Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis. JAMA Dermatol. 2020;156(4):421–429. https://doi.org/10.1001/jamadermatol.2020.0024.; Rademaker M, Rubel DM, Agnew K, Andrews M, Armour KS, Baker C et al. Psoriasis and cancer. An Australian/New Zealand narrative. Australas J Dermatol. 2019;60:12–18. https://doi.org/10.1111/ajd.12889.; Loft ND, Vaengebjerg S, Skov L. Cancer risk in patients with psoriasis: Should we be paying more attention? Expert Rev Clin Immunol. 2020;16:479–492. https://doi.org/10.1080/1744666X.2020.1754194.; Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence. Clin Cosmet Investig Dermatol. 2022;15:1649–1658. https://doi.org/15:1649‐1658.; Geller S, Xu H, Lebwohl M, Nardone B, Lacouture ME, Kheterpal M. Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update. Am J Clin Dermatol. 2018;19(3):363–375. https://doi.org/10.1007/s40257-017-0337-2.; Shah IA. Beneficial Role of Vitamin D in Common Cancers: Is the Evidence Compelling Enough? WCRJ. 2020;7:e1574. https://doi.org/10.32113/wcrj_20205_1574.; Collins L, Asfour L, Stephany M, Lear JT, Stasko T. Management of Nonmelanoma Skin Cancer in Transplant Recipients. Clin Oncol. 2019;31(11):779–788. https://doi.org/10.1016/j.clon.2019.08.005.; Paul CF, Gourraud PA. Cancer risk evaluation in psoriasis: in search of the Holy Grail? J Invest Dermatol. 2009;129(11):2547–2549. https://doi.org/10.1038/jid.2009.203.; He MM, Lo CH, Wang K, Polychronidis G, Wang L, Zhong R et al. Immunemediated diseases associated with cancer risks. JAMA Oncol. 2022;8(2):209–219. https://doi.org/10.1001/jamaoncol.2021.5680.; Wang X, Wang X, Wang H, Yang M, Dong W, Shao D. Association between psoriasis and lung cancer: two-sample Mendelian randomization analyses. BMC Pulm Med. 2023;23(1):4. https://doi.org/10.1186/s12890-022-02297-0.; Rusiñol L, Camiña-Conforto G, Puig L. Biologic treatment of psoriasis in oncologic patients. Expert Opin Biol Ther. 2022;22(12):1567–1578. https://doi.org/10.1080/14712598.2022.2152322.; Borren NZ, Ananthakrishnan AN. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Metaanalysis. Clin Gastroenterol Hepatol. 2019;17(9):1736–1743.e4. https://doi.org/10.1016/j.cgh.2018.12.032.; Palakornkitti P, Nimmannitya K, Rattanakaemakorn P. Biological therapy in Psoriasis: An emphasis on its dermatologic adverse events. Asian Pac J Allergy Immunol. 2021;39(4):215–230. https://doi.org/10.12932/AP110521-1129.; Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. https://doi.org/10.1016/j.jaad.2018.11.057.; Wu S, Xu Y, Yang L, Guo L, Jiang X. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Front Immunol. 2023;14:1294416. https://doi.org/10.3389/fimmu.2023.1294416.; Puig L, Notario J, López-Ferrer A, Scheneller-Pavelescu L, Pérez B, Galache C et al. Recommendations from the Spanish Academy of Dermatology and Venereology Psoriasis Working Group on the Management of Patients with Cancer and Psoriasis. Actas Dermosifiliogr. 2024;115(7):702–711. https://doi.org/10.1016/j.ad.2024.02.013.; Wang X, Liu Q, Wu L, Nie Z, Mei Z. Risk of non-melanoma skin cancer in patients with psoriasis: An updated evidence from systematic review with meta-analysis. J Cancer. 2020;11(5):1047–1055. https://doi.org/10.7150/jca.37015.; Trafford AM, Parisi R, Kontopantelis E, Griffiths CEM, Ashcroft DM. Association of Psoriasis With the Risk of Developing or Dying of Cancer: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019;155(12):1390–1403. https://doi.org/10.1001/jamadermatol.2019.3056.; Lambert JLW, Segaert S, Ghislain PD, Hillary T, Nikkels A, Willaert F et al. Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2). J Eur Acad Dermatol Venereol. 2020;34(9):1914–1923. https://doi.org/10.1111/jdv.16683.; Amatore F, Villani AP, Tauber M, Viguier M, Guillot B; Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie). French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464–483. https://doi.org/10.1111/jdv.15340.; Thatiparthi A, Martin A, Liu J, Wu JJ. Risk of Skin Cancer with Phototherapy in Moderate-to-Severe Psoriasis: An Updated Systematic Review. J Clin Aesthet Dermatol. 2022;15(6):68–75. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239121.; Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J et al. Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. Ann Intern Med. 2020;172(6):369–380. https://doi.org/10.7326/M19-3369.; Polesie S, Gillstedt M, Schmidt SAJ, Egeberg A, Pottegård A, Kristensen K. Use of methotrexate and risk of skin cancer: a nationwide case-control study. Br J Cancer. 2023;128(7):1311–1319. https://doi.org/10.1038/s41416-023-02172-7.; Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281–317. https://doi.org/10.1111/jdv.16926.; Carrascosa JM, de la Cueva P, Ara M, Puig L, Bordas X, Carretero G et al. Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations. Actas Dermosifiliogr. 2016;107(3):194–206. https://doi.org/10.1016/j.ad.2015.10.005.; Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255–1268. https://doi.org/10.1016/j.jaad.2020.03.132.; Cutroneo P, Ingrasciotta Y, Isgrò V, Rullo EV, Berretta M, Fiorica F et al. Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors. Dermatol Ther. 2021;34(2):e14830. https://doi.org/10.1111/dth.14830.; Said JT, Elman SA, Perez-Chada LM, Mita C, Merola JF, LeBoeuf NR. Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review. J Am Acad Dermatol. 2022;87(2):399–400. https://doi.org/10.1016/j.jaad.2022.02.030.; Johnson D, Patel AB, Uemura MI, Trinh VA, Jackson N, Zobniw CM et al. IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. Cancer Immunol Res. 2019;7(6):860–865. https://doi.org/10.1158/2326-6066.Cir-18-0682.
Nájsť tento článok vo Web of Science